Back to Search Start Over

Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing

Authors :
Sandling, Johanna K.
Pucholt, Pascal
Hultin Rosenberg, Lina
Farias, Fabiana H. G.
Kozyrev, Sergey V
Eloranta, Maija-Leena
Alexsson, Andrei
Bianchi, Matteo
Padyukov, Leonid
Bengtsson, Christine
Jonsson, Roland
Omdal, Roald
Lie, Benedicte A.
Massarenti, Laura
Steffensen, Rudi
Jakobsen, Marianne A.
Lillevang, Soren T.
Lerang, Karoline
Molberg, Oyvind
Voss, Anne
Troldborg, Anne
Jacobsen, Soren
Syvanen, Ann-Christine
Jonsen, Andreas
Gunnarsson, Iva
Svenungsson, Elisabet
Rantapaa-Dahlqvist, Solbritt
Bengtsson, Anders A.
Sjöwall, Christopher
Leonard, Dag
Lindblad-Toh, Kerstin
Ronnblom, Lars
Sandling, Johanna K.
Pucholt, Pascal
Hultin Rosenberg, Lina
Farias, Fabiana H. G.
Kozyrev, Sergey V
Eloranta, Maija-Leena
Alexsson, Andrei
Bianchi, Matteo
Padyukov, Leonid
Bengtsson, Christine
Jonsson, Roland
Omdal, Roald
Lie, Benedicte A.
Massarenti, Laura
Steffensen, Rudi
Jakobsen, Marianne A.
Lillevang, Soren T.
Lerang, Karoline
Molberg, Oyvind
Voss, Anne
Troldborg, Anne
Jacobsen, Soren
Syvanen, Ann-Christine
Jonsen, Andreas
Gunnarsson, Iva
Svenungsson, Elisabet
Rantapaa-Dahlqvist, Solbritt
Bengtsson, Anders A.
Sjöwall, Christopher
Leonard, Dag
Lindblad-Toh, Kerstin
Ronnblom, Lars
Publication Year :
2021

Abstract

Objectives Systemic lupus erythematosus (SLE) is an autoimmune disease with extensive heterogeneity in disease presentation between patients, which is likely due to an underlying molecular diversity. Here, we aimed at elucidating the genetic aetiology of SLE from the immunity pathway level to the single variant level, and stratify patients with SLE into distinguishable molecular subgroups, which could inform treatment choices in SLE. Methods We undertook a pathway-centred approach, using sequencing of immunological pathway genes. Altogether 1832 candidate genes were analysed in 958 Swedish patients with SLE and 1026 healthy individuals. Aggregate and single variant association testing was performed, and we generated pathway polygenic risk scores (PRS). Results We identified two main independent pathways involved in SLE susceptibility: T lymphocyte differentiation and innate immunity, characterised by HLA and interferon, respectively. Pathway PRS defined pathways in individual patients, who on average were positive for seven pathways. We found that SLE organ damage was more pronounced in patients positive for the T or B cell receptor signalling pathways. Further, pathway PRS-based clustering allowed stratification of patients into four groups with different risk score profiles. Studying sets of genes with priors for involvement in SLE, we observed an aggregate common variant contribution to SLE at genes previously reported for monogenic SLE as well as at interferonopathy genes. Conclusions Our results show that pathway risk scores have the potential to stratify patients with SLE beyond clinical manifestations into molecular subsets, which may have implications for clinical follow-up and therapy selection.<br />Funding Agencies|AstraZeneca-Science for Life Laboratory Research Collaboration grant (DISSECT); Swedish Research Council for Medicine and Health [2018-02399, 2018-02535]; Swedish Rheumatism Association; King Gustav Vs 80-year Foundation; Swedish-Heart-Lung foundationSwedish Heart-Lung Foundation; Wallenberg Scholar Award; Swedish Society of Medicine; Science for Life Laboratory; Swedish Research Council (VR-RFI)Swedish Research Council; Uppsala University; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1248701367
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1136.annrheumdis-2020-218636